Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
about
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myelomaA novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic diseaseTargeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modelingDual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaFunctional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Proteomic analysis of multiple myeloma: current status and future perspectives.Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapySST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.Advances in discovering small molecules to probe protein function in a systems context.Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBPSynergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myelomaA Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer.Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.A niche opportunity for stem cell therapeutics.Syndecan-1: a dynamic regulator of the myeloma microenvironment.Transcription factors as therapeutic targets in lymphoid malignancies.Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsClinical development of novel proteasome inhibitors for cancer treatment.Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization.Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivoA novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.Identification of EpCAM as a molecular target of prostate cancer stroma.C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1.Development of target-specific treatments in multiple myeloma.Drug-mediated and cellular immunotherapy in multiple myeloma.Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.Tetraspanins stimulate protein synthesis in myeloma cell lines.Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
P2860
Q24598483-B3D4D61A-258E-43CD-B8A8-B89053D90F5CQ27329429-7205313C-15FA-4A9D-A7B9-03BDF4194741Q27334339-CA85C03A-0FF8-4174-877D-F74C355E427AQ28271286-6188A744-6B47-426E-BAA0-4409384F72BEQ30490975-18D6F570-6A1A-4B42-8E89-9CF13FB8E8BAQ30802505-FC9CA1E6-AE92-4032-92BA-B5D0F7DFCE07Q33400076-9C3E4952-6B5F-4BE6-A0F7-1AD317B18D55Q33585559-5D7D2AD3-9D09-4942-AA42-0327595064D3Q33627051-19178F9E-2BE7-49CD-9CDC-AA4473DDD714Q33692555-F7A7FD6F-47C0-4A99-81AF-A62A304AB767Q33807327-2751E7D7-4556-4CAA-AF6F-34AD385856E8Q34075717-06E38DA8-345A-4F7F-9AC7-60141D56FBD9Q34134986-05C04381-CCC2-4416-ACCB-CE2F63B58574Q34552894-A36B8941-1002-40FD-9B08-5EE3F4264859Q34694466-156FAA22-7373-4E1D-A4E7-A1FF7A6A362BQ35854932-7BB9BBBB-9433-440B-8718-C938F1E5664DQ36092102-F0AAB1FC-E0EB-47EE-9FFF-C0B8C8EFC7BCQ36338365-81B7F56B-68A2-4056-90BC-A31404380F5AQ36447976-DA370951-7026-42C0-ADD4-85DE5A7C8759Q36470302-60E24C8F-F322-467A-A498-52804C8359D6Q36579136-F5F60937-6FA6-469B-BF2E-856BC58E3BE3Q36724717-D838FB21-52D9-415E-B924-408F6F14ABE8Q36984165-3D6D0A6C-A88B-434C-BF04-9825AF94FB93Q37001382-C2C3D62B-44E4-462C-A264-6E7DD9BD7067Q37008599-17A128A2-FD21-4AF1-9C03-7E0740BE9108Q37008654-A51F0163-E50E-4438-8BC1-35F468F04FEBQ37008882-6CEDECD7-9EBF-40F4-B788-0F4B062BA223Q37017342-A4709F73-1790-4069-A2AE-23A36E590EAFQ37136598-06802199-528C-4314-A055-38659E41DA5FQ37185154-46B376B2-AE72-4219-9B74-A460F6D10A8DQ37377754-C99F1D03-9E63-41DA-BAE4-F29066B2131BQ37389377-E39AB774-7E78-438A-BF74-4EAA8503AF9AQ37462612-AF8195EE-A2A1-4FDC-A995-09D508C59A65Q37600370-778E0770-0545-4308-BABF-495511D5B9DCQ37771370-3AF6F526-1050-4A26-9BE3-792D277CE520Q37773257-D624651A-847A-426A-B1B0-76E1C9C8AE45Q38016511-54A33F03-5FAE-4D2D-AC64-5B1A8F23F98EQ38887338-8D601486-D63F-4807-BCBC-6EEE40344046Q39380162-A59AE680-9E1D-4411-882B-373561178AF1Q39510395-89EBB03A-391E-4C7E-B7CA-A76C0763A213
P2860
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
@ast
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
@en
type
label
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
@ast
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
@en
prefLabel
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
@ast
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
@en
P1476
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
@en
P2093
Kenneth C Anderson
P304
P356
10.1016/J.EXPHEM.2007.01.024
P433
P577
2007-04-01T00:00:00Z